| Item 7.01. | Regulation FD Disclosure. |
On December 18, 2023, Akero Therapeutics, Inc. (the “Company”) issued a press release titled “Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
On December 18, 2023, the Company announced that patients have received their first doses of efruxifermin (“EFX”) in its Phase 3 clinical study of EFX in the treatment of patients with biopsy-confirmed non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease (“NASH/MASH”), fibrosis stage 2 or 3 (F2-F3).
SYNCHRONY Histology will evaluate the efficacy of 28mg and 50mg doses of EFX in patients with biopsy confirmed pre-cirrhotic NASH, F2-F3. The primary endpoint will be ≥ 1-stage fibrosis improvement and resolution of NASH.
SYNCHRONY Real-World will assess safety and tolerability of EFX in patients with non-invasively diagnosed NASH or NAFLD.
Key secondary endpoints in both Phase 3 studies will include changes in biomarkers of liver fibrosis as well as measures of glycemic control and lipids.
Forward-Looking Statements
Statements contained under this Item 8.01 regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, statements regarding the potential therapeutic effects of EFX, the SYNCHRONY Phase 3 program, including the SYNCHRONY Histology and SYNCHRONY Real-World studies and design of trials. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Akero’s product candidate development activities and planned clinical trials; Akero’s ability to execute on its strategy; positive results from any of its clinical studies may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; Akero’s ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption “Risk Factors” in Akero’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission (SEC) as well as discussions of potential risks, uncertainties and other important factors in
